Additionally, the cutoff values for utilizing anti-PD-L1 agents differ by cancer type: for Pembrolizumab (anti PD-1 monoclonal antibody), TPS ≥ 1% is required for non-small cell lung cancer (NSCLC), CPS ≥ 1 for head and neck squamous cell carcinoma (HNSCC) and cervical cancer, and for patients with triple-negative breast cancer and esophageal or gastroesophageal junction tumors, a CPS greater than 10 is necessary. Here, CD274 is linked to head and neck squamous cell carcinoma.